Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma

BACKGROUND: Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma. Adding other active agents may enhance treatment efficacy. METHODS: The primary objective of this factorial phase II study was to determine if one of 3 potential chemotherapy ag...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Penas-Prado, Marta, Hess, Kenneth R., Fisch, Michael J., Lagrone, Lore W., Groves, Morris D., Levin, Victor A., De Groot, John F., Puduvalli, Vinay K., Colman, Howard, Volas-Redd, Gena, Giglio, Pierre, Conrad, Charles A., Salacz, Michael E., Floyd, Justin D., Loghin, Monica E., Hsu, Sigmund H., Gonzalez, Javier, Chang, Eric L., Woo, Shiao Y., Mahajan, Anita, Aldape, Kenneth D., Yung, W. K. Alfred, Gilbert, Mark R.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2015
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4288521/
https://ncbi.nlm.nih.gov/pubmed/25239666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou155
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars